SL1108_18 Aptamer Details
ID# 8242
Structure
Chemistry
DNA
Target
RBD of SARS-COV-2 Spike protein (monomer or trimer)
Category
Protein
Affinity (Kd)
0.4-0.6 nM
Length
35
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dTpdCpdGpdGpdApdApdTpdGpdApdApdTpdGpdTpdCpdTpdGpdCpdCpdTpdTpdGpdCpdApdCpdTpdGpdGpdTpdGpdCpdGpdGpdTpdCpdCp-3'
Molecular Weight:
Extinction Coefficient:
Binding Conditions / Buffer
37°C
Binding Temp: NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Gelinas, A. D., Tan, T. K., Liu, S., Jaramillo, J. G., Chadwick, J., Harding, A. C., Zhang, C., Ream, B. E., Chase, C. N., Otis, M. R., Lee, T., Schneider, D. J., James, W. S., & Janjic, N. (2023). Broadly neutralizing aptamers to SARS-COV-2: A diverse panel of modified DNA antiviral agents. Molecular Therapy - Nucleic Acids, 31, 370–382. https://doi.org/10.1016/j.omtn.2023.01.008
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
